CSI Market
Sign In | Register

Anixa Biosciences Inc (ANIX) Annual Income Statement

Annual · GAAP · USD millions
Access ANIX quarterly income statements →
This income statement overview for Anixa Biosciences Inc spans from Oct 31 2020 to Oct 31 2025, showing how the company's revenues, expenses, and earnings have changed across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Oct 31 2025)
2025 		(Oct 31 2024) (Oct 31 2023) (Oct 31 2022) (Oct 31 2020)
Revenues
Revenue From Contract With Customer Excluding Assessed Tax0.00
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing6.63
Research and Development Expense5.07
Unusual Expense / Income0.00
Total operating costs including COS11.70
Operating income / -loss-11.70
Interest Income-0.67
Net Interest (-)Expense / Income0.67
Other loss / -income0.00
Total costs & expenses11.03
Income & Taxes
Income / -loss before income taxes-11.03
Income after income taxes-11.03
Income / -loss from continuing operations-11.03
Non-controlling interests-0.10
Net income / -loss-11.03
Income / -loss to shareholder-10.93
EBIT-11.70
EBITD-11.70
EBITDA-11.70
Earnings Per Share
Basic EPS (excl. extra items)-0.34
Basic Net EPS-0.34
Basic shares outstanding (Mill. of Units)32.45
Diluted Net EPS-0.34
Diluted average shares (Mill. of Units)32.45
4 historic quarters locked

Sign in to unlock the full Anixa Biosciences Inc income statement history.

Sign In Create Free Account

About Anixa Biosciences Inc Annual Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-K filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-K filings
  • Filed with the SEC: January 12, 2026
  • Original filing: form10-k.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.